Questions? Chat with the founder on WhatsApp

Chat with the founder on WhatsApp
Arthneeti
HomeRankingsIPOScreenerInstitutions
HomeRankingsIPOScreenerInstitutions
GPT Healthcare LtdQ1 FY27Healthcare Services
Home/Stocks/GPT Healthcare Ltd/Q1 FY27

GPT Healthcare Ltd Q1 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹150P/E: 27.1Market Cap: ₹1.3K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • →GPT Healthcare expects continued revenue growth driven by higher occupancy and improved specialty mix across hospitals.
  • →Mature hospitals show steady patient inflows with network occupancy at 45.5%, and 58.07% in mature hospitals excluding Raipur.
  • →Expansion projects like the 155-bed Jamshedpur hospital commissioning in Q4 FY27 and plans for a seventh hospital will increase capacity beyond 1,000 beds in 2 years.
  • →Specialty services, including liver transplants (around 10 per year initially at Raipur), oncology ramp-up, and robotic surgeries, are expected to drive higher ARPOB and patient volumes.
  • →Newer hospitals like Raipur and Dumdum are ramping up occupancy and revenue, with Dumdum targeting optimum occupancy by Q3 FY27.
  • →International patient inflows from Bangladesh are improving but expected to normalize fully in 6 months, adding to growth.
  • →Overall, the company targets sustainable earnings growth, aiming for around 21% EBITDA margin and ROE/ROCE of ~25% over medium term.

Margin guidance

Category 1
  • →GPT Healthcare expects EBITDA margins to improve from 19% last year to around 21% in FY27, translating to an EBITDA of approximately INR 110-115 crores annually (including other income).
  • →Profit after tax for Q1 FY27 stood at INR 12.7 crores with a PAT margin of 9.9%, reflecting strong growth and resilience.
  • →The company targets long-term ROE and ROCE of around 25%, driven by occupancy improvement, specialty mix optimization, and asset-light expansion.
  • →New hospital ramps (Raipur, Jamshedpur) and expansion plans for a 7th hospital will drive network growth beyond 1,000 beds over 2 years.
  • →Growth supported by higher ARPOB led by specialty care, optimized occupancy, and innovative services like robotic surgeries and transplant programs.
  • →Profitability expected to improve as Raipur's losses taper and Jamshedpur hospital ramps up, with historical breakeven achieved in 12-20 months for new hospitals.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes
  • →No significant change in debt position compared to last year; debt remains stable.
  • →Jamshedpur hospital project will incur additional debt of around INR 25 crores in the current fiscal year.
  • →No specific mention of raising equity or new fundraising plans during the call.
  • →Future expansion (7th hospital) may involve acquisitions or greenfield projects; no direct indication of fundraising method disclosed.
  • →The company maintains a healthy balance sheet and focuses on disciplined capital allocation.
  • →Overall, plans rely on prudent capital use rather than immediate large-scale fundraising through debt or equity.

Order book

The transcript does not explicitly mention details about the current or expected order book or pending orders for GPT Healthcare Limited. However, relevant insights include: - The company is progressing with the construction of a 155-bed tertiary care hospital at Jamshedpur, expected to be commissioned in Q4 FY27. - Evaluation of opportunities for a seventh hospital is ongoing, targeting Tier 1 and Tier 2 cities like Cuttack, Ranchi, Patna, Banaras, and Prayagraj. - Both greenfield and acquisition opportunities are being considered, with no definitive order or project confirmed yet. - Asset-light models are being used for new hospitals like Raipur and Jamshedpur to reduce capital investment. Therefore, while active projects and expansions are in the pipeline, there is no specific mention of an order book or pending orders figure in the transcript.

Capex plans

Yes
  • →GPT Healthcare is progressing on the construction of a 155-bed tertiary care hospital in Jamshedpur, expected to be commissioned in Q4 FY27.
  • →The company is evaluating opportunities for a seventh hospital, aiming to increase network capacity to over 1,000 beds in the next 2 years.
  • →Expansion plans include both acquisition and greenfield projects in Tier 1 and Tier 2 cities like Cuttack, Ranchi, Patna, Banaras, and Prayagraj.
  • →New hospitals such as Raipur and Jamshedpur are developed on an asset-light model, leasing customized buildings to reduce real estate investments.
  • →GPT Healthcare is investing in advanced medical technologies, strengthening high-acuity specialties, and expanding transplant programs.
  • →Focus remains on disciplined growth through capacity expansion, stronger clinical capabilities, and prudent capital allocation.

How does GPT Healthcare Ltd rank vs peers in Healthcare Services?

Pro feature
1GPT Healthcare Ltd
Rev 3Mar 1
2Healthcare Services Company A
Rev 1Mar 2
3Healthcare Services Company B
Rev 2Mar 1
4Healthcare Services Company C
Rev 2Mar 3

See full Healthcare Services sector rankings

How does GPT Healthcare Ltd rank in Healthcare Services?

Compare GPT Healthcare Ltd against every Healthcare Services company (Q1 FY27) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Related research

Read the full Q1 FY27 earnings insight — GPT Healthcare Ltd

Other quarters — GPT Healthcare Ltd

Q4 FY26Q3 FY26Q2 FY26Q1 FY26Q4 FY25Q3 FY25Q2 FY25Q1 FY25Q4 FY24Q3 FY24

Healthcare Services peers

Apollo Hospitals Enterprise Ltd · Q4 FY26Fortis Health. · Q1 FY27Syngene Intl. · Q4 FY26Dr Lal Pathlabs · Q1 FY27Narayana Hrudaya · Q1 FY27
GPT Healthcare Ltd full stock analysisHealthcare Services sectorEarnings call directoryRankings dashboard

Questions about this analysis? Chat directly with the founder — real answers about the research, not a support bot.

WhatsApp the founder

Research team or advisory firm? Get earnings-call intelligence and ranking history as research inputs for your firm.

For Institutions

Arthneeti AI

AI-powered stock analysis from earnings call transcripts. Helping Indian investors make smarter decisions with data-driven insights.

Analysis

  • Stock Rankings
  • Sectors
  • Compare Stocks
  • IPO Dashboard
  • Stock Screener
  • Earnings Call Analysis
  • Stocks Under ₹500
  • Multibaggers

Tools

  • MF Overlap Checker
  • SIP Calculator
  • CAGR Calculator
  • FD vs Equity
  • All Calculators

Resources

  • Blog
  • Weekly Digest
  • Portfolio Analysis
  • Build Portfolio
  • Earnings Calendar
  • Q1 FY27 Earnings Hub

Company

  • Pricing
  • How Our Analysis Works
  • For Institutions
  • Terms of Service
  • Privacy Policy

Compare

  • vs Screener.in
  • vs Trendlyne
  • vs Tickertape
  • vs Moneycontrol Pro
+91 90841 32575 support@arthneeti.com Bengaluru, India

© 2026 Arthneeti AI. All rights reserved.

AI-analyzed data from 1,500+ company earnings calls

Continue your research

What GPT Healthcare Ltd's management said in earlier quarters

  • Q1 FY27 earnings call analysis →
  • Q2 FY26 earnings call analysis →
  • Q4 FY25 earnings call analysis →
  • Q3 FY26 earnings call analysis →

Others in Healthcare Services this season

  • Rainbow Childrens Medicare Ltd (Q1 FY27)

    Volume growth supported by planned addition of 2,500 beds over 5 years (~15% CAGR) (Page 10). Key concall takeaways from Rainbow Childrens Medicare Ltd's Q1…

  • Dr Lal Pathlabs (Q1 FY27)

    140 crore to Rs. Key concall takeaways from Dr Lal Pathlabs's Q1 FY27 earnings call — and how it ranks against sector peers.

  • Vimta Labs Ltd (Q1 FY27)

    The company's various business units are growing at almost double the industry's CAGR (8%-11%). Key concall takeaways from Vimta Labs Ltd's Q1 FY27 earnings…

  • Dr Agarwal's Hea (Q1 FY27)

    Q1 FY27 revenue from operations grew 26% year-on-year to INR614 crores, driven by both volume and value growth (~16% each). Key concall takeaways from Dr…

Compare:vs Apollo Hospitals Enterprise Ltdvs Max Healthcarevs Fortis Health.